Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Payables (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Payables readings, the most recent being $2.6 million for Q1 2026.

  • On a quarterly basis, Payables rose 171.94% to $2.6 million in Q1 2026 year-over-year; TTM through Jan 2026 was $2.6 million, a 171.94% increase, with the full-year FY2025 number at $991169.0, down 12.1% from a year prior.
  • Payables hit $2.6 million in Q1 2026 for Pharma-Bio Serv, up from $991169.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.8 million in Q1 2024 to a low of $874379.0 in Q3 2025.
  • Median Payables over the past 5 years was $1.5 million (2023), compared with a mean of $1.5 million.
  • Biggest five-year swings in Payables: tumbled 65.83% in 2025 and later skyrocketed 171.94% in 2026.
  • Pharma-Bio Serv's Payables stood at $1.6 million in 2022, then decreased by 9.95% to $1.5 million in 2023, then dropped by 23.15% to $1.1 million in 2024, then decreased by 12.1% to $991169.0 in 2025, then skyrocketed by 161.06% to $2.6 million in 2026.
  • The last three reported values for Payables were $2.6 million (Q1 2026), $991169.0 (Q4 2025), and $874379.0 (Q3 2025) per Business Quant data.